Get the app
HealthcareBusiness & Enterprise

AI Biotech Enveda Doubles in Value to $2 Billion

Covered by 2 sources
Read the full article
Enveda Biosciences, supported by a former Johnson & Johnson CEO, has doubled its valuation to $2 billion as it prepares to advance its drug candidates into late-stage clinical trials.

Covered by 2 sources

#biotechnology#drug-development#enveda-biosciences#johnson-and-johnson

More in Healthcare

Healthcare32 min read

Development of an automated method for audiometric data extraction and analysis using voting optical character recognition

Nature
Healthcare3 min read

Microsoft Says Its New AI Is Better at Diagnosing Patients Than Real Doctors

Futurism
Healthcare2 min read

UK government sets out $800 million for AI security funding

ET AI (The Economic Times)